The Russian Sputnik V vaccine is 92% effective in protecting other People from Covid-19 based on the effects of intermediate trials, the country’s sovereign fund said Wednesday, as Moscow rushes to keep speed with Western drug brands in the vaccine race.
The effects of Russia are only the moment in a complex human trial, temporarily after knowledge published Monday through Pfizer Inc and BioNTech, which said that its injection is also more than 90% effective.
While experts said Russian knowledge was encouraging and reinforced the concept that the pandemic could be stopped by vaccines, they warned that the effects were based on only a small number of test volunteers who had Covid-19.
Research conducted after 20 participants developed the virus and tested how many had won the vaccine compared to a placebo, which is particularly lower than the 94 infections in the pfizer and BioNTech vaccine trial.
“I suppose there was political tension after the Pfizer and BioNTech press release earlier in the week to now get closer to their own data,” said Bodo Plachter, deputy director of the Institute of Virology at the University of Mainz. “What’s missing at the moment is statistically significant research. “
To verify the effectiveness rate of his vaccine, Pfizer said he would continue his test until there are 164 instances of Covid-19.
The Russian Direct Investment Fund (DRIF), which supports Sputnik V, said the Russian test would continue for six months.
Alexander Gintsburg, director of the Gamaleya Institute that developed the vaccine, said the interim effects showed that Sputnik V is effective and that mass vaccines will be deployed in Russia in the coming weeks.
European stocks and US equity futures are in the middle of the world. But it’s not the first time They prolonged their gains slightly after Russia’s announcement, the reaction was much more moderate than after Pfizer’s results.
Chinese company Sinopharm, which is conducting complex large-scale clinical trials for two COVID-19 vaccine candidates, said Wednesday that its knowledge was greater than expected, giving additional details.
‘IT’S NOT A COMPETITION’
Effective vaccines are considered essential to restore life around the world by helping to end the pandemic that has killed more than 1. 26 million people, closed businesses and left millions out of work.
However, experts said that wisdom about the design of the Russian check is scarce, making it difficult to interpret the data.
Scientists have expressed their fear of the speed Moscow has worked at, giving the regulatory approval to shoot and launch mass vaccines before the complete protective and effective tests are completed.
“It’s not a competition. We want all trials to be conducted to the highest criteria imaginable and it is essential that the predefined criteria are met to cancel the blindness of the knowledge of the trial to avoid conforming to cherry knowledge,” said Eleanor Riley, professor of immunology and Infectious Diseases. University of Edinburgh.
“Anything but this jeopardizes public confidence in all vaccines, which would be a disaster. “
The effects are based on the knowledge of the first 16,000 trial participants to obtain two-dose vaccine injections.
“We show, based on the data, that we have a very effective vaccine,” RDIF director Kirill Dmitriev said, adding that this is the kind of news that vaccine developers will one day communicate with their grandchildren.
The so-called phase III trial of the vaccine is being conducted in 29 moscow clinics and will have a total of 40,000 volunteers, of whom a quarter will receive a position.
The chances of getting Covid-19 decreased by 92% among those vaccinated with Sputnik V than among those who gained placebo, RDIF said.
This is above the 50% efficacy threshold for Covid-19 vaccines established by the US Food and Drug Administration. But it’s not the first time
RDIF stated that knowledge would be published in a leading medical journal after peer review. The effects of early Russian trials were peer reviewed and published in September in the medical journal The Lancet.
Experts said that, as with Pfizer’s results, it is not yet clear how long immunity will last after receiving the Russian vaccine, or how effective it would be for other age groups.
“We want longer-term observations to draw valid conclusions about efficacy and side effects. The same goes for Pfizer and BioNTech figures,” Plachter said in Mainz.
SPUTNIK V
Russian drugs are called Sputnik V by the Soviet-era satellite that sparked the race, a nod to the geopolitical importance of the project to Russian President Vladimir Putin.
Russia registered the vaccine for public use in August, the first country to do so, before the start of the large-scale trial in September.
So far, he has inoculated 10,000 members of the public to be at the highest threat of covid-19, as doctors and teachers, outdoors during the trial.
The vaccine is designed to cause a reaction from two injections given 21 days apart, each based on other viral vectors that cause the unusual cold: the human adenovirus Ad5 and Ad26.
The Pfizer vaccine and BioNTech uses messenger RNA generation (mRNA) and is designed to cause an immune reaction without pathogens, such as real viral particles.
Russia is also another vaccine, produced through the Vector Institute in Siberia, and is about to sign a third vaccine, Putin said Tuesday, adding that all vaccines in the country were effective.
RDIF stated that, as of 11 November, no serious side effects had been reported from the Sputnik V Phase III trial.
Some volunteers had minor short-term adverse occasions, such as at the injection site, a flu syndrome that included fever, weakness, fatigue and headaches, he said.
At the end of October, vaccination of new volunteers was temporarily discontinued due to increased demand and lack of doses.
Russia’s deputy prime minister said Wednesday that the Vector Institute vaccine will be tested after registration on November 15.
Russia has reported 19,851 new coronavirus infections in more than 24 hours and a record 432 deaths. At 1,836,960, its total number of instances is fifth in the world, the United States, India, Brazil and France.
This uses cookies to give you the most productive browsing experience.
Learn more or your settings.
What are cookies
As is a popular practice on almost all professional websites, our site uses cookies, which are small files downloaded to your device, for your experience.
This document describes the data they collect, how we use it, and why we want to purchase those cookies. We will also provide a percentage of how you can save the garage from those cookies, however, this may simply degrade or “break” some elements of the site. Functionality.
How we use cookies
We use cookies for the reasons listed below. Unfortunately, in most cases, there is no popular option in the industry to disable cookies without absolutely disabling the features and functions they upload to the site. It is recommended to leave all cookies if you are not sure that you want to use them or not, in case they are used to provide a service you are using.
The types of cookies used in this can be classified into one of 3 categories:
Disable cookies
You can prevent cookies from being set by adjusting your browser settings (see your browser’s “Help” option to learn how to do this). Please note that disabling cookies may cause this online page and many other websites you visit. , it is advised not to disable cookies.
Third party cookies
In some express cases, we also use cookies provided through trusted third parties. Our site uses [Google Analytics], one of the maximum, non-unusual and reliable analytical responses on the web, to help us perceive how you use the site and how we can these cookies may track parts such as the time you spend on the site and the pages on which you stop so that we can continue to produce interesting content. To learn more about Google Analytics cookies, visit the official Google Analytics page.
Google analitico
Google Analytics is Google’s analytics tool that helps our online page perceive how visitors interact with its properties. You can use a set of cookies to collect data and generate online page usage statistics without identifying individual Google visitors. The main cookie used through Google Analytics is the “__ga” cookie.
In addition to online page usage statistics, Google Analytics may also be used, along with some advertising cookies, to display more applicable classified ads in Google homes (such as Google search) and on the web, and to measure interactions with Google classified ads. .
Learn more about Analytics cookies and privacy information.
Using IP to deal with. An IP protection is a virtual code that identifies your device on the Internet. We may use its IP interface and browser type to analyze usage patterns and diagnose disorders on this online page and the service we offer you. But without further information, your IP does not identify you as an individual.
Your choice. When you accessed this website, our cookies were sent to your internet browser and stored on your device. On our website, you agree to the use of cookies and similar technologies.
Learn more
Hopefully, the above data has clarified things to you. As discussed above, if you are not sure whether you need to allow cookies or not, it is safer to leave cookies enabled in case they interact with any of the features you use on our site. However, if you are looking for more information, feel free to contact us by email at [email protected]
Strictly mandatory cookies must be enabled at all times so that we can record your personal tastes for cookie settings.
If you disable this cookie, we will not record your preferences, which means that each and every time you visit this website, you will need to turn cookies on or off again.